Abstract
We conducted a simple prospective trial studied influence of pentoxifylline on the course of active pulmonary sarcoidosis in 70 patients. This drug decreasing TNF-α (tissue necrosis factor-α) level was given orally in the dose of 600 mg 3 times a day in combination with α-to copherol in the dose of 400 IU twice a day. Fourteen patients stopped treatment because of side effects (nausea, dizziness). Fifty-six patients had clinical improvement in 71.4 % of cases, reduction of intrathoracic lymphadenopathy in 71.8 %, reliable improvement in DLCO (lung diffusing capacity for carbon monoxide) and increase in the blood lymphocyte count. The clinical effectiveness of this drug combination was less in chronic sarcoidosis and in patients who had taken systemic glucocorticosteroids or antituberculotics before. A multicentral comparative trial is required to include pentoxifylline to guidelines on management sarcoidosis patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
